Neurologic manifestations of inflammatory disease final

Case 1 SF
• 41 y/o woman with no PMHx p/w blurry
vision and headache worsening x few
weeks. No meds, no toxic habits.
• PE: Afeb VSS. Bilateral lid swelling.
• Neuro exam: MSE with mild cognitive
slowing and diminished attention,
otherwise normal. CN: diminished VA with
disc swelling b/l.
• Motor/sensory/cerebellar intact.
Other w/u
• LP: elevated opening pressure, CSF
lymphocytic pleocytosis (60-80), prt 80
• Serum ACE: ~65
• CSF ACE: ~20
Clinical course
• Progressive cognitive decline, recurring
bouts of aseptic meningitis with visual
blurring partially responsive to IV steroids.
• Poor compliance pulse Cytoxan
• Later developed poor vision d/t glaucoma
and b/l optic neuritis
• Panhypopituitarism
• Dementia
Case 2 RC
• 44 y/o man with hx of CVA and behavioral
problems, p/w AMS and difficulty walking.
Prior CVA admitted at Montefiore 2005,
p/w . W/u revealed basal ganglia and
cerebellar calcification on CT scan, acute
R midbrain/thalamic infarct on MRI.
Cause of stroke in young uncertain,
however pt found to be ANA+.
• Meds:
• PE: Afeb VSS
Neuro: MSE: alert, Ox2, dim attention, STM
CN: dysarthric, otherwise intact
Motor: increased tone in legs, full strength,
mild incoordination on FTN,
DTRs: hyperactive
Gait: spastic/ataxic
Other w/u
ESR 120
Creatinine 2-3 (prior baseline 1-1.5)
ANA and dsDNA+
Anti-cardiolipin Ab+
MRI spinal cord: no significant abnl
Cerebral angiogram: possibly slight
medium vessel irregularity c/w
Clinical course
IV steroids
Worsening dementia and paraparesis
D/c to SNF
CNS Inflammatory Disease
• Primary, recurrent demyelinating diseases: MS,
Neuromyelitis Optica (NMO, Devic’s Dx)
• Mono-phasic demyelinating diseases: Acute
disseminated encephalomyelitis (ADEM), acute
hemorrhagic leukoencephalitis (AHLE), transverse
myelitis (TM), optic neuritis (ON); often these are parainfectious
• CNS involvement with systemic (clinical or sub-clinical)
auto-immune disease; includes primary and secondary
CNS vasculitis
• Paraneoplastic dx
• Immune reconstitution inflammatory syndrome (IRIS)
• CNS infections (discussed in other lecture)
Systemic inflammatory conditions with
frequent neurological manifestations
SLE neuropsychiatric manifestations
Anti-phospholipid Ab syndrome (1º or 2º)
Rheumatoid arthritis: PNS
Vasculitis: large or small vessel
Large: Giant cell arteritis: CN>CVA
Small: Wegener’s, polyarteritis nodosum: mononeuritis
multiplex > CN >>CNS
• Paraneoplastic syndromes: cerebellar dx, limbic
encephalitis, PNS
Focal Clinical Presentation
• Focal CNS deficit (brain or brainstem):
hemiparesis, hemisensory loss, hemiataxia,
diplopia, vertigo, dysarthria
• Spinal cord syndrome: complete
(motor/sensory/autonomic), anterior, posterior,
Brown Sequard
• Cranial nerve: optic neuritis, trigeminal
neuralgia, facial paresis
• Pseudo-peripheral: Lhermitte’s sign,
paresthesias, pain
• Focal cognitive deficit: aphasia, apraxia, neglect
Neuropyschiatric SLE:
19 syndromes described
Joseph (2007) Neurology
Neurological dx present in: ~50% (15-90%)
Presenting with neuro symptoms: 3-5%
NPSLE worsens prognosis
NPSLE can occur without systemic flare
Lab abnl: ESR elevated 50%, ANA+ 85%,
dsDNA+ 72%, anti-phospholipid Ab 30%,
complement low during flare 44%, ribosomal P
Ab and C3A frequently elevated prior to/during
• APS associated with NPSLE, CVA, other focal
Neuro testing in NPSLE
• CSF abnl: 20-40% (lymphocytic
pleocytosis, elevated prt, OCB each
present in ~20%).
• EEG abnl: up to 80% abnl, mostly nonspecific changes but some with
epileptogenic focus.
• EMG/NCS: high% abnl in symptomatic
PNS dx
• Brain MRI: abnl in 20-70%; most common
findings are multifocal small white matter
hyperintensities and atrophy; stroke in <
20%; lower % show basal ganglia
calcification, reversible
leukoencephalopathy syndrome (RPLS).
• SPECT: detects multifocal or
patchy/diffuse perfusion deficits in 50-90%
• MR spectroscopy: abnl in ? 20-50%
MRI abnl in NPSLE pts
Csepany (2003) J Neurol
Sanna 2003
CNS Lupus
Csepany 2003
Lupus RPLS
Magnano 2006
EMT with SLE, APS, complicated
migraine with aphasia and RHP
• Neurological manifestations in ~10%
(~20% at autopsy).
• Rarely presents with neurologic syndrome
• Very rarely limited to NS %
Joseph (2008) JNNP
Spencer (2004) Sem Arthritis Rheum
Laboratory findings in
CXR abnl: ~40-50% (30-80% range)
Chest CT abnl: ~60-75% (? up to 90%)
Gallium/PET scan abnl: 25-80%
Serum ACE elevation: 25-75%
CSF prt elevation: 50%
CSF lymphocytic pleocytosis: 40%
CSF OCB: 20-40%
Neurosarcoid MRI abnl
• Any abnl: up to 80%
• Leptomeningeal or parenchymal
enhancement: 25-50%
• White matter lesions: 30-50%
Neurological manifestations of
Sjogren’s syndrome
• Common disorder, affecting ~2-3% of
• Neurological dx present in 5-60%.
• CNS and PNS dx both common.
• Neurological symptoms occur prior to
diagnosis in 80-90% of patients.
• Sicca symptoms present in <50% at
PNS Sjogren’s
Mori (2005) Brain
MRI, path, and sweat testing in Sjogren’s
sensory neuropathy (Mori 2005)
Lab abnl in Neuro-Sjogren’s
SSA/SSB+: 45%
Schirmer’s test abnl: 90%
Salivary scintography abnl: 65%
Lip bx abnl: 95%
Joseph (2008) JNNP
Sanna (2003) Lupus
Csepany et al (2003) J Neurol
Mori (2005) Brain
Delalande (2004) Medicine
Soliotis (1999) Ann Rheum Dis
Joseph (2008) JNNP
Joseph (2007) Practical neurology
Spencer (2004) Sem Arthritis Rheum
Spenser 2004
CNS Sjogren’s
Related flashcards
Create Flashcards